Loading...
XSTO
CEVI
Market cap496mUSD
Jun 09, Last price  
199.60SEK
1D
2.89%
1Q
20.97%
Jan 2017
132.09%
IPO
1,471.65%
Name

CellaVision AB

Chart & Performance

D1W1MN
No data to show
P/E
33.83
P/S
6.58
EPS
5.90
Div Yield, %
1.13%
Shrs. gr., 5y
Rev. gr., 5y
9.39%
Revenues
723m
+6.78%
74,565,000100,444,000108,974,000131,638,000155,402,000169,512,000179,851,000216,916,000239,390,000265,038,000309,312,000364,812,000461,772,000471,443,000565,552,000639,340,000677,292,000723,217,000
Net income
141m
+7.99%
2,625,00025,054,00027,720,00038,349,00014,633,0006,451,00018,932,00031,465,00052,822,00059,800,00069,723,00088,688,00099,172,00089,480,000125,339,000118,335,000130,309,000140,722,000
CFO
198m
+1.02%
6,666,0001,270,00020,580,00011,458,00032,015,00011,493,00027,272,00039,784,00087,997,00076,567,00087,898,00074,069,000125,993,00071,124,000159,717,000137,285,000196,436,000198,438,000
Dividend
May 07, 20252.5 SEK/sh

Profile

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
IPO date
May 28, 2007
Employees
235
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
723,217
6.78%
677,292
5.94%
639,340
13.05%
Cost of revenue
545,539
510,240
481,074
Unusual Expense (Income)
NOPBT
177,678
167,052
158,266
NOPBT Margin
24.57%
24.66%
24.75%
Operating Taxes
36,138
33,913
30,094
Tax Rate
20.34%
20.30%
19.01%
NOPAT
141,540
133,139
128,172
Net income
140,722
7.99%
130,309
10.12%
118,335
-5.59%
Dividends
(53,666)
(53,666)
(47,703)
Dividend yield
1.03%
1.06%
0.87%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
14,171
36,039
42,131
Long-term debt
12,678
59,611
98,249
Deferred revenue
Other long-term liabilities
6,254
4,945
3,739
Net debt
(122,581)
(30,391)
26,987
Cash flow
Cash from operating activities
198,438
196,436
137,285
CAPEX
(77,749)
(31,769)
(69,434)
Cash from investing activities
(76,006)
(85,532)
(70,014)
Cash from financing activities
(95,089)
(97,036)
(90,410)
FCF
150,139
134,318
61,076
Balance
Cash
149,430
121,645
108,053
Long term investments
4,396
5,340
Excess cash
113,269
92,176
81,426
Stockholders' equity
705,589
630,828
Invested Capital
848,829
693,861
666,378
ROIC
18.35%
19.58%
20.95%
ROCE
19.35%
19.76%
19.77%
EV
Common stock shares outstanding
23,852
23,852
23,852
Price
217.50
2.59%
212.00
-7.42%
229.00
-29.58%
Market cap
5,187,711
2.59%
5,056,624
-7.42%
5,462,108
-29.58%
EV
5,065,130
5,026,233
5,489,095
EBITDA
177,678
206,815
198,363
EV/EBITDA
28.51
24.30
27.67
Interest
8,159
3,260
2,340
Interest/NOPBT
4.59%
1.95%
1.48%